Myasthenia Gravis
Myasthenia gravis is a chronic autoimmune condition in which the immune system attacks the junction between nerves and muscles. The result is muscle weakness that tends to worsen during activity and improve with rest. It is uncommon but occurs across Asia, including in Japan, South Korea, and Southeast Asia, where registry data suggest it may be slightly more prevalent in younger women than in Western populations.
Medicine used to treat Myasthenia Gravis
How myasthenia gravis is managed
The condition does not yet have a cure, but symptoms can be controlled effectively. The mainstay of symptomatic treatment is pyridostigmine, a cholinesterase inhibitor that allows acetylcholine to accumulate at the nerve-muscle junction, improving signal transmission. Longer-term management typically also involves immunosuppression to reduce the underlying autoimmune attack. A neurology specialist usually oversees care, adjusting therapy as symptoms fluctuate. Anyone experiencing sudden severe weakness, difficulty swallowing, or breathing difficulty should seek emergency care immediately, as these can signal a myasthenic crisis.